Molecular genetic testing strategies used in diagnostic flow for hereditary endocrine tumour syndromes.

Affiliation

Butz H(1)(2)(3), Blair J(4), Patócs A(5)(6)(7)(8).
Author information:
(1)Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
(2)Hereditary Cancers Research Group, Hungarian Academy of Sciences-Semmelweis University, Budapest, Hungary.
(3)Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary.
(4)Alder Hey Children's Hospital-NHS Foundation Trust, Liverpool, United Kingdom.
(5)Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. [Email]
(6)Hereditary Cancers Research Group, Hungarian Academy of Sciences-Semmelweis University, Budapest, Hungary. [Email]
(7)Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary. [Email]
(8)Semmelweis University, Budapest, Hungary. [Email]

Abstract

INTRODUCTION: Although current guidelines prefer the use of targeted testing or small-scale gene panels for identification of genetic susceptibility of hereditary endocrine tumour syndromes, next generation sequencing based strategies have been widely introduced into every day clinical practice. The application of next generation sequencing allows rapid testing of multiple genes in a cost effective manner. Increasing knowledge about these techniques and the demand from health care providers and society, shift the molecular genetic testing towards using high-throughput approaches. PURPOSE: In this expert opinion, the authors consider the molecular diagnostic workflow step by step, evaluating options and challenges of gathering family information, pre- and post-test genetic counselling, technical and bioinformatical analysis related issues and difficulties in clinical interpretation focusing on molecular genetic testing of hereditary endocrine tumour syndromes. RESULT AND CONCLUSION: Considering all these factors, a diagnostic genetic workflow is also proposed for selection of the best approach for testing of patients with hereditary genetic tumour syndromes in order to minimalize difficult interpretation, unwanted patient anxiety, unnecessary medical interventions and cost. There are potential benefits of utilizing high throughput approaches however, important limitations have to be considered and should discussed towards the clinicians and patients.